Vaxcyte at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Vaxcyte brings 3 presentations to IDWeek 2026 in Washington, and exhibits at Booth BS 16, BS 25. Its program centres on pneumococcal vaccines for adults and on how the company designs new vaccines. One analysis projects how its investigational vaccine would affect public health in US adults compared with other pneumococcal conjugate vaccines.
| Organization | IDWeek 2026 Attendance |
|---|---|
Vaxcyte San Carlos, CA | |
Vaccine company developing broader-coverage pneumococcal conjugate vaccines, led by VAX-31, a 31-valent candidate in Phase 3 trials. | Booth Exhibiting at Booth BS 16, BS 25 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 1:30pm–1:50pm Poster Sat Oct 24 12:15pm–1:30pm Design and Rationale of the Phase 3 OPUS-1, OPUS-2, and OPUS-3 Trials Evaluating a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults Poster Sat Oct 24 12:15pm–1:30pm Projected Public Health Impacts of PCV20, PCV21, and VAX-31, a 31-Valent Investigational Pneumococcal Conjugate Vaccine, in US Adults |
Instantly find 20 buyers from Vaxcyte
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction